Synergistic Lethal Mutagenesis of Hepatitis C Virus-Reference-Cited by-同舟云学术

Synergistic Lethal Mutagenesis of Hepatitis C Virus

Published:2019-12 Issue:12 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Gallego Isabel¹²,Soria María Eugenia¹,Gregori Josep²³⁴,de Ávila Ana I.¹,García-Crespo Carlos¹,Moreno Elena¹,Gadea Ignacio⁵,Esteban Jaime⁵,Fernández-Roblas Ricardo⁵,Esteban Juan Ignacio²³⁶,Gómez Jordi²⁷,Quer Josep²³⁶,Domingo Esteban¹²,Perales Celia¹²⁵

Affiliation:

1. Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain

2. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) del Instituto de Salud Carlos III, Madrid, Spain

3. Liver Unit, Internal Medicine Hospital Universitari Vall d’Hebron, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain

4. Roche Diagnostics, S.L., Sant Cugat del Vallés, Spain

5. Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain

6. Universitat Autónoma de Barcelona, Barcelona, Spain

7. Instituto de Parasitología y Biomedicina López-Neyra (CSIC), Parque Tecnológico Ciencias de la Salud, Armilla, Granada, Spain

Abstract

Lethal mutagenesis is an antiviral approach that consists of extinguishing a virus by an excess of mutations acquired during replication in the presence of a mutagenic agent, often a nucleotide analogue. One of its advantages is its broad-spectrum nature, which renders the strategy potentially effective against emergent RNA viral infections. Here we describe the synergistic lethal mutagenesis of hepatitis C virus (HCV) by a combination of favipiravir (T-705) and ribavirin.

Funder

Ministerio de Economia y Competitividad

CIBER Enfermedades Hepáticas y Digestivas

MEC | Instituto de Salud Carlos III

Comunidad de Madrid

Ministerio de Ciencia, Innovación y Universidades

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01653-19

Reference98 articles.

1. Eigen M, Schuster P. 1979. The hypercycle. A principle of natural self-organization. Springer, Berlin, Germany.

2. MUTATION LOAD AND THE SURVIVAL OF SMALL POPULATIONS

3. Holland JJ. 1990. Defective viral genomes, p 151–165. In Fields BM, Knipe DM, Chanock RM, Hirsch MS, Melnick JL, Monath TP, Roizman B (ed), Fields virology, 2nd ed. Raven Press, New York, NY.

4. Lethal mutagenesis of HIV with mutagenic nucleoside analogs

5. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergism between remdesivir and ribavirin leads to SARS‐CoV‐2 extinction in cell culture;British Journal of Pharmacology;2024-04-14

2. Atypical Mutational Spectrum of SARS-CoV-2 Replicating in the Presence of Ribavirin;Antimicrobial Agents and Chemotherapy;2023-01-24

3. Efficacy decrease of antiviral agents when administered to ongoing hepatitis C virus infections in cell culture;Frontiers in Microbiology;2022-08-03

4. SARS-CoV-2 Point Mutation and Deletion Spectra and Their Association with Different Disease Outcomes;Microbiology Spectrum;2022-04-27

5. Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity;Viruses;2022-04-18